Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study
Dermatologic Therapy — Anna C, Atzori L, Potenza C, et al. | August 03, 2021
Results demonstrate real-life evidence of a high level of satisfaction with efficacy and convenience of the Calcipotriol/betamethasone dipropionate (Cal/BD) foam in a cohort of plaque psoriasis patients, with an objective improvement in Psoriasis Area Severity Index (PASI) in this observational study.
Researchers recruited a total of 256 patients who were eligible, with a mean age of 55.6 (15.4) years, 59.4% were males.
In 52.0% of patients, psoriasis severity was mild, it was moderate in 43.3%, and severe in 4.7%.
There was scalp involvement in 36.7% of patients.
Furthermore, 80.5% of patients received previous antipsoriatic treatments.
Results showed that TSQM-9 median (25th-75th percentile) scores were 83.3 (66.7–88.9) for effectiveness, 77.8 (66.7–88.9) for convenience, and 78.6 (64.3–92.9) for global satisfaction.
After 4 weeks, the mean PASI value reduced from 7.3 (4.8) to 2.1 (2.7).
It has been reported that more than 90% of individuals previously treated for psoriasis evaluated the Cal/BD foam more effectively, easier to use, and better tolerated in comparison with previous topical treatments at patient preference questionnaires.
Read the full article on Dermatologic Therapy